CN105209014B - 含有肉毒杆菌神经毒素的药物组合物及其应用 - Google Patents

含有肉毒杆菌神经毒素的药物组合物及其应用 Download PDF

Info

Publication number
CN105209014B
CN105209014B CN201480027168.XA CN201480027168A CN105209014B CN 105209014 B CN105209014 B CN 105209014B CN 201480027168 A CN201480027168 A CN 201480027168A CN 105209014 B CN105209014 B CN 105209014B
Authority
CN
China
Prior art keywords
botulinum toxin
composition
chitosan
composition according
series
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480027168.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105209014A (zh
Inventor
E·波库谢洛夫
V·福缅科
N·萨拉赫迪诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOSTI TRADING Ltd
Original Assignee
BOSTI TRADING Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOSTI TRADING Ltd filed Critical BOSTI TRADING Ltd
Publication of CN105209014A publication Critical patent/CN105209014A/zh
Application granted granted Critical
Publication of CN105209014B publication Critical patent/CN105209014B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480027168.XA 2013-05-15 2014-05-14 含有肉毒杆菌神经毒素的药物组合物及其应用 Expired - Fee Related CN105209014B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013122509/15A RU2535115C1 (ru) 2013-05-15 2013-05-15 Фармацевтический состав, содержащий нейротоксин ботулина
RU2013122509 2013-05-15
PCT/IB2014/061417 WO2014184746A1 (en) 2013-05-15 2014-05-14 Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof

Publications (2)

Publication Number Publication Date
CN105209014A CN105209014A (zh) 2015-12-30
CN105209014B true CN105209014B (zh) 2018-05-25

Family

ID=50841919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027168.XA Expired - Fee Related CN105209014B (zh) 2013-05-15 2014-05-14 含有肉毒杆菌神经毒素的药物组合物及其应用

Country Status (10)

Country Link
US (1) US10258673B2 (enExample)
EP (2) EP2996674B1 (enExample)
JP (1) JP6440691B2 (enExample)
CN (1) CN105209014B (enExample)
CA (1) CA2911046C (enExample)
DK (1) DK2996674T3 (enExample)
ES (1) ES2829614T3 (enExample)
HK (1) HK1217173A1 (enExample)
RU (1) RU2535115C1 (enExample)
WO (1) WO2014184746A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738739B2 (ja) * 2014-04-30 2020-08-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 膀胱内滴下注入用生物製剤
SG11201700736YA (en) * 2014-07-31 2017-02-27 Allergan Inc Formulations of biologics for intravesical instillation
RU2577296C1 (ru) * 2014-12-24 2016-03-10 Евгения Николаевна Анисимова Способ выбора эффективного и безопасного местного обезболивания у пациентов с артериальной гипертензией на амбулаторном стоматологическом приеме
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
WO2019005222A1 (en) * 2017-06-29 2019-01-03 Advaite LLC. TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS
JP7395576B2 (ja) * 2018-06-13 2023-12-11 デルマタ・セラピューティクス，インコーポレーテッド 皮膚状態の処置のための組成物
KR20210057106A (ko) * 2018-09-13 2021-05-20 알레간 인코포레이티드 교근 비대의 치료 방법
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
EP4045073A4 (en) 2019-10-18 2022-12-07 Penland Foundation Botulinum toxin for use in treatment
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2024102345A1 (en) * 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046065A1 (en) * 2004-10-29 2006-05-04 Ipsen Limited Botulinum toxin therapy of heart rhythm disorders
US20060182767A1 (en) * 2002-05-28 2006-08-17 Borodic Gary E High-potency botulinum toxin formulations
US20120141532A1 (en) * 2007-12-12 2012-06-07 Blanda Wendy M Botulinum Toxin Formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884358A (en) 1957-04-22 1959-04-28 Southern California Gland Co Process for preparing crude heparin
JPH06192296A (ja) 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US8073538B2 (en) * 2003-11-13 2011-12-06 Cardio Polymers, Inc. Treatment of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
EP1691747B1 (en) * 2003-11-13 2012-05-23 CardioPolymers, Inc. Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
JP2005306746A (ja) * 2004-04-19 2005-11-04 Jiyugaoka Clinic 顔面用シワ治療剤
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2007019554A2 (en) * 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
EP2476392A1 (en) 2006-05-15 2012-07-18 Symphony Medical, INC. Post-operative control of cardiac arrhythmia by modification of neuronal signaling through fat pads of the heart
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP4999008B2 (ja) 2008-07-15 2012-08-15 楽天株式会社 情報送信装置、情報送信方法、情報送信処理プログラム及び情報送信システム
HUE037595T2 (hu) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
JP6738739B2 (ja) * 2014-04-30 2020-08-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 膀胱内滴下注入用生物製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182767A1 (en) * 2002-05-28 2006-08-17 Borodic Gary E High-potency botulinum toxin formulations
WO2006046065A1 (en) * 2004-10-29 2006-05-04 Ipsen Limited Botulinum toxin therapy of heart rhythm disorders
US20120141532A1 (en) * 2007-12-12 2012-06-07 Blanda Wendy M Botulinum Toxin Formulation

Also Published As

Publication number Publication date
DK2996674T3 (da) 2020-10-26
CA2911046C (en) 2021-08-31
JP2016518442A (ja) 2016-06-23
US10258673B2 (en) 2019-04-16
CN105209014A (zh) 2015-12-30
EP2996674B1 (en) 2020-08-12
JP6440691B2 (ja) 2018-12-19
CA2911046A1 (en) 2014-11-20
HK1217173A1 (zh) 2016-12-30
US20160114013A1 (en) 2016-04-28
EP3750525A1 (en) 2020-12-16
ES2829614T3 (es) 2021-06-01
RU2535115C1 (ru) 2014-12-10
WO2014184746A1 (en) 2014-11-20
EP2996674A1 (en) 2016-03-23

Similar Documents

Publication Publication Date Title
CN105209014B (zh) 含有肉毒杆菌神经毒素的药物组合物及其应用
US12171816B2 (en) Non-protein Clostridial toxin compositions
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
Crockford Development of thymosin β4 for treatment of patients with ischemic heart disease
AU2017227978A1 (en) Composition comprising botulinum toxin
EP2768523A1 (en) Method of treating or reducing efp
You et al. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis
Gong et al. Injectable Hydrogel for Cardiac Repair via Dual Inhibition of Ferroptosis and Oxidative Stress
Oliveira Effectiveness of hyaluronidase on degrading hyaluronic acid
US20250295741A1 (en) Prevention of post-operative atrial fibrillation with a botulinum toxin
TW202002954A (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
RU2832647C1 (ru) Композиция, содержащая ботулинический токсин
HK40054617A (en) Clostridial toxin-hyaluronic acid compositions
Caicco Hyaluronan-Methylcellulose Hydrogels for Cell and Drug Delivery to the Injured Central Nervous System
NZ624057B2 (en) Method of treating or reducing efp

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180525

CF01 Termination of patent right due to non-payment of annual fee